the problem is unless a biotech introduces penalty clauses in a contract with Cro or maintains strong oversight of what the Cro is doing, like is on at them almost daily, there is little incentive for a Cro to do anything quickly. They’ll be happy to keep getting the monthly cheque as long as the study keeps going.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-118
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
